Trial Profile
Phase Ib/II Clinical Trial of Glembatumumab Vedotin and Nivolumab in Advanced Solid Tumors
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Glembatumumab vedotin (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Advanced breast cancer; Solid tumours; Triple negative breast cancer; Uveal melanoma
- Focus Adverse reactions; Therapeutic Use
- 17 Jul 2018 Planned End Date changed from 29 Aug 2020 to 22 Apr 2018.
- 17 Jul 2018 Planned primary completion date changed from 29 Aug 2020 to 21 Apr 2018.
- 17 Jul 2018 Planned initiation date changed from 29 Jun 2018 to 20 Apr 2018.